ResMed Inc

RMD: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
?KxLOCK|<&q&LOCK|#q!xrpJ

ResMed Earnings: Volume Drives Solid Start, but Some Earnings Benefits Will Reverse

ResMed’s fiscal first-quarter 2027 revenue rose 6% to USD 1.41 billion, while EPS increased 14% to USD 2.91. Gross margin expanded 50 basis points to 62.5% on manufacturing productivity gains and delayed US facility costs. Management reiterated its fiscal 2027 guidance.

Sponsor Center